10-12 week paid internship
The Intern, Computational Biology Science contributes scientific and technical expertise to an
interdisciplinary team focused on making large-scale clinical impact through advanced analysis and
science. The Intern identifies biomarkers in tumor DNA and RNA, collaborates with other scientific
teams to enrich analysis, and contributes other projects as needed.
Principal Duties and Responsibilities:
Contribute to methods and algorithms to identify alterations and biomarkers in tumor DNA
sequencing and RNA sequencing data derived from clinical cancer specimens.
Process, analyze, and interpret high volumes of data for the development and validation of methods.
Present scientific and technical data to colleagues in a clear and cohesive manner.
Work independently and prepare deliverables and project schedules.
Ability to work independently with minimal supervision; an urge to excel and achieve results
Excellent verbal and written communication skills
Currently enrolled in an accredited college or university, pursuing a Master's degree or PhD in biology,
computer science, computational biology, bioinformatics, or a related field. Proficient with programming
and scripting languages (Python, Java, or R).
Bachelor's Degree in biology, computer science, computational biology, bioinformatics, or a related field.
Prior experience with next-generation sequencing data. Strong scientific understanding of molecular
biology and genomics. Demonstrated instances of relevant independent study or projects. Excellent
teamwork and leadership skills demonstrated through a portfolio of graduate study related work, and/or
activities. Strong time management and organizational skills. Ability to work independently in a
multidisciplinary, fast-paced, dynamic, and results-oriented environment. Commitment to reflect H3B’s
values: Patients, Passion, Innovation and Collaboration.
H3 Biomedicine Inc. is a privately held, uniquely structured oncology discovery enterprise whose sole
mission is to become a prolific source of new drugs that treat more human cancers with greater success.
H3B is applying the expertise of leading scientists to the integration of insights from cancer genomics
with innovative capabilities in synthetic chemistry and tumor biology to pursue the most promising
current opportunity in cancer therapeutics: patient-based, genomics-driven, small molecule drugs.